Statin trial aims to boost immune system against prostate cancer
NCT ID NCT05586360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether taking simvastatin, a common cholesterol drug, for 8 weeks before prostate surgery can improve the immune system's ability to fight prostate cancer. Half of the 36 men with localized prostate cancer will receive the drug, while the other half will receive standard care. The study looks at changes in immune cells within the prostate to see if the drug reduces cancer-friendly immune activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Simvastatin 40mg
What this could lead to
If it works, this could point toward a way to use a common cholesterol drug to help the immune system fight prostate cancer.
What could go wrong
This is a small, early-phase trial with only 36 men, so results may not apply to everyone. The drug may not change immune activity as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University
NOT_YET_RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Hollings Cancer Center at Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
Contact